William Robert Wilson

William Robert Wilson's AcademicInfluence.com Rankings

Philosophy

#7175

World Rank

#10347

Historical Rank

Logic

#4245

World Rank

#5514

Historical Rank

philosophy Degrees

William Robert Wilson

Biology

#9747

World Rank

#12989

Historical Rank

Ecology

#541

World Rank

#594

Historical Rank

Biochemistry

#1501

World Rank

#1629

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

William Robert Wilson's Degrees

Doctorate Medicine Harvard University

Why Is William Robert Wilson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William Robert Wilson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Targeting hypoxia in cancer therapy (2011) (2515)
Exploiting tumour hypoxia in cancer treatment (2004) (2314)
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review. (2016) (655)
Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104 (2007) (211)
A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. (1984) (190)
Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards. (1993) (163)
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. (2010) (151)
Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. (1989) (150)
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. (2006) (145)
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine (2016) (142)
DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258) (1994) (129)
Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104 (2011) (120)
Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. (1986) (114)
Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors (2010) (111)
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. (1998) (107)
Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. (2010) (105)
Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. (1998) (104)
Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. (2003) (103)
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) (2002) (100)
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors (2010) (92)
Structure−Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine (2003) (92)
Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia (2000) (92)
Interaction of the antitumor drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids. (1981) (89)
Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. (1984) (89)
Therapeutic targeting of the hypoxic tumour microenvironment (2021) (86)
Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. (1995) (84)
Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. (1994) (82)
Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukaemia cell lines. (1986) (82)
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. (2007) (81)
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia (2015) (80)
2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT (2004) (77)
Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. (1990) (76)
DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity. (2009) (75)
Selective toxicity of nitracrine to hypoxic mammalian cells. (1984) (75)
Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. (2002) (75)
The Design of Selectively‐activated Anti‐cancer Prodrugs for use in Antibody‐directed and Gene‐directed Enzyme‐Prodrug Therapies * (1998) (71)
Synthesis, structures and hypoxia-selective cytotoxicity of cobalt(III) complexes containing tridentate amine and nitrogen mustard ligands (2000) (70)
Comparison of the mutagenic and clastogenic activity of amsacrine and other DNA-intercalating drugs in cultured V79 Chinese hamster cells. (1984) (69)
DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. (1990) (68)
The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia (2011) (67)
Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells. (2008) (66)
Hypoxia-selective antitumor agents. 8. Bis(nitroimidazolyl)alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. (1994) (65)
Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. (2006) (64)
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients (2011) (64)
Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. (2007) (64)
Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia (2012) (63)
Bystander Effects of Bioreductive Drugs: Potential for Exploiting Pathological Tumor Hypoxia with Dinitrobenzamide Mustards (2007) (63)
Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A (2009) (62)
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. (1994) (61)
Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation. (2003) (61)
Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins. (2008) (61)
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. (2015) (59)
Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. (1992) (59)
DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine. (2004) (59)
E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954 (2009) (58)
Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. (2000) (58)
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. (2003) (57)
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours (2012) (56)
Recent developments in the design of bioreductive drugs. (1996) (52)
SIDE-EFFECTS OF IVERMECTIN IN TREATMENT OF ONCHOCERCIASIS (1989) (51)
A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. (1999) (51)
Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores. (2003) (51)
Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. (1995) (51)
Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. (2005) (50)
Hypoxia-selective antitumor agents. 1. Relationships between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivatives of nitracrine. (1989) (50)
Pulse Radiolysis Studies on the Fragmentation of Arylmethyl Quaternary Nitrogen Mustards by One-Electron Reduction in Aqueous Solution (1997) (50)
Design and synthesis of cobalt(III) nitrogen mustard complexes as hypoxia selective cytotoxins. The X-ray crystal structure of bis(3-chloropentane-2,4-dionato)(RS-N,N′-bis(2-chloroethyl)ethylenediamine)cobalt(III) perchlorate, [Co(Clacac)2(bce)]ClO4 (1991) (50)
Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae (2019) (49)
The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR (2007) (49)
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. (2000) (48)
DNA strand cleavage by the phenazine di-N-oxide natural product myxin under both aerobic and anaerobic conditions. (2012) (47)
AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. (2015) (47)
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104 (2013) (46)
Nitro reduction as an electronic switch for bioreductive drug activation. (1997) (45)
Dual pH-sensitive liposomes with low pH-triggered sheddable PEG for enhanced tumor-targeted drug delivery. (2019) (45)
Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents. (2009) (45)
Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins. (2011) (45)
Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. (1996) (44)
Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771. (1994) (44)
Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine derivatives. (1989) (44)
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. (2018) (43)
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy. (2007) (42)
Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs) (1993) (42)
Selective Potentiation of the Hypoxic Cytotoxicity of Tirapazamine by Its 1-N-Oxide Metabolite SR 4317 (2004) (42)
Targeting hypoxia in the leukemia microenvironment. (2013) (41)
Reductive metabolism and hypoxia-selective toxicity of nitracrine. (1986) (41)
Oxygen Dependence of the Metabolic Activation and Cytotoxicity of Tirapazamine: Implications for Extravascular Transport andActivity in Tumors (2004) (41)
Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity. (2007) (41)
Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides. (2018) (40)
Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs. (2012) (40)
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. (1996) (39)
Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. (1994) (39)
Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer (2014) (39)
Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins. (2009) (39)
Synthesis and Cytotoxicity of 5-Amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2- dihydro-3H-benz[e]indole (Amino-seco-CBI-TMI) and Related 5-Alkylamino Analogues: New DNA Minor Groove Alkylating Agents (1998) (38)
Bis-tropolonato derivatives of cobalt(III) complexes of bidentate aliphatic nitrogen mustards as potential hypoxia-selective cytotoxins. (1997) (38)
Prediction of Tumour Tissue Diffusion Coefficients of Hypoxia-Activated Prodrugs from Physicochemical Parameters (2008) (38)
DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. (1990) (37)
Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport. (2007) (37)
Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program (2011) (37)
Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. (1992) (37)
Optimization of the Auxiliary Ligand Shell of Cobalt(III)(8-hydroxyquinoline) Complexes as Model Hypoxia-Selective Radiation-Activated Prodrugs (2004) (36)
Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling (2013) (36)
Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy. (2005) (36)
Anionic carbonato and oxalato cobalt(III) nitrogen mustard complexes. (2004) (36)
Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. (1996) (34)
The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. (1990) (34)
Activity of 4'-(9-acridinylamino)methanesulfon-m-anisidide against Chinese hamster cells in multicellular spheroids. (1981) (33)
18F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non–Small Cell Lung Cancer Xenograft Model (2013) (33)
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase. (2003) (33)
Hypoxia-selective antitumor agents. 4. Relationships between structure, physicochemical properties, and hypoxia-selective cytotoxicity for nitracrine analogues with varying side chains: the "iminoacridan hypothesis". (1990) (33)
Cross-bridged cyclen or cyclam Co(III) complexes containing cytotoxic ligands as hypoxia-activated prodrugs. (2013) (33)
Evaluation of potential health effects of 10 kHz magnetic fields: a rodent reproductive study. (1998) (33)
Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators (2009) (32)
Mechanism of resistance of noncycling mammalian cells to 4'-(9-acridinylamino)methanesulfon-m-anisidide: comparison of uptake, metabolism, and DNA breakage in log- and plateau-phase Chinese hamster fibroblast cell cultures. (1988) (32)
Bis(dialkyl)dithiocarbamato cobalt(III) complexes of bidentate nitrogen mustards: synthesis, reduction chemistry and biological evaluation as hypoxia-selective cytotoxins. (1998) (32)
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase. (2004) (32)
PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation (2018) (32)
Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. (1994) (31)
Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins. (1992) (31)
Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5. (2014) (31)
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity (2011) (30)
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. (2014) (30)
Hypoxia-selective radiosensitization of mammalian cells by nitracrine, an electron-affinic DNA intercalator. (1987) (30)
Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. (1996) (30)
A NOVEL ENEDIYNE PRODRUG FOR ANTIBODY-DIRECTED ENZYME PRODRUG THERAPY (ADEPT) USING E. COLI B NITROREDUCTASE (1995) (30)
Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography-mass spectrometry. (2007) (29)
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma (2011) (29)
Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity. (1999) (29)
Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. (2000) (29)
Expression and role in glycolysis of human ADP-dependent glucokinase (2012) (28)
Aerobic 2- and 4-nitroreduction of CB 1954 by human liver. (2005) (28)
Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures. (1981) (28)
Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts. (1998) (28)
NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. (1992) (28)
Potential of DMXAA combination therapy for solid tumors (2002) (28)
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. (2003) (28)
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice (2011) (28)
Radiosensitization of mammalian cells in vitro by nitroacridines. (1990) (28)
Structure-activity relationships for thiolytic cleavage rates of antitumor drugs in the 4'-(9-acridinylamino)methanesulfonanilide series. (1976) (27)
FSL-61 is a 6-nitroquinolone fluorogenic probe for one-electron reductases in hypoxic cells. (2013) (27)
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma (2015) (27)
Mechanism of resistance of non-cycling mammalian cells to 4'-[9-acridinylamino]methanesulphon-m-anisidide: role of DNA topoisomerase II in log- and plateau-phase CHO cells. (1988) (27)
N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization. (1999) (27)
Design, Synthesis and Evaluation of Imidazolylmethyl Carbamate Prodrugs of Alkylating Agents (2000) (27)
Cell-cycle-stage specificity of 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and interaction with ionizing radiation in mammalian cell cultures. (1981) (27)
An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids (2018) (27)
5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits. (1999) (26)
DNA-directed alkylating agents. 4. 4-anilinoquinoline-based minor groove directed aniline mustards. (1991) (26)
Tumour hypoxia: challenges for cancer chemotherapy (1992) (26)
Characterization of a smart pH‐cleavable PEG polymer towards the development of dual pH‐sensitive liposomes (2018) (25)
A novel nitro-substituted seco-CI: Application as a reductively activated adept prodrug (1996) (25)
Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. (1989) (25)
Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility. (1995) (25)
Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). (1999) (25)
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia (2019) (25)
The Morphological Effects Of The Anti‐Tumor Agents Flavone Acetic Acid And 5,6‐Dimethyl Xanthenone Acetic Acid On The Colon 38 Mouse Tumor (1994) (25)
pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells. (2017) (24)
Pulse radiolysis studies of electron migration in DNA from DNA base-radical anions to nitroacridine intercalators in aqueous solution (1991) (24)
Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy. (2010) (23)
Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice. (1983) (23)
Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid. (1998) (22)
Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans (2010) (22)
Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. (2016) (21)
Rapid and sensitive ultra-high-pressure liquid chromatography-tandem mass spectrometry analysis of the novel anticancer agent PR-104 and its major metabolites in human plasma: Application to a pharmacokinetic study. (2009) (21)
Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins showing very high in vitro selectivity. (1993) (21)
An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect12 (2018) (21)
Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures (2018) (21)
The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs. (2014) (21)
Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence* (2013) (20)
Cellular pharmacology of evofosfamide (TH‐302): A critical re‐evaluation of its bystander effects (2018) (20)
N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs. (2011) (19)
Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1. (1996) (19)
Evaluation of potential health effects of 10 kHz magnetic fields: a short-term mouse toxicology study. (1996) (19)
Nitrobenzyl mustard quaternary salts: a new class of hypoxia-selective cytotoxins capable of releasing diffusible cytotoxins on bioreduction. (1994) (19)
Glucuronidation of Anticancer Prodrug PR-104A: Species Differences, Identification of Human UDP-Glucuronosyltransferases, and Implications for Therapy (2011) (18)
Resistance of cultured Lewis lung carcinoma cell lines to tiazofurin. (1987) (18)
Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase. (1996) (18)
Ocular involvement in patients with onchocerciasis after repeated treatment with ivermectin. (1990) (18)
Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine by radiation. (1998) (18)
N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. (1995) (18)
SYNTHESIS AND CYTOTOXICITY OF AMINO-SECO-DSA : AN AMINO ANALOGUE OF THE DNA ALKYLATING AGENT DUOCARMYCIN SA (1999) (17)
Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. (2001) (17)
Synthesis and hypoxia-selective cytotoxicity of a 2-nitroimidazole mustard. (1998) (16)
Zinc Finger Nuclease Mediated Knockout of ADP-Dependent Glucokinase in Cancer Cell Lines: Effects on Cell Survival and Mitochondrial Oxidative Metabolism (2013) (16)
Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice (2017) (16)
Hypoxia-selective antitumor agents. 15. Modification of rate of nitroreduction and extent of lysosomal uptake by polysubstitution of 4-(alkylamino)-5-nitroquinoline bioreductive drugs. (1997) (16)
5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine. (1992) (16)
Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures. (1987) (15)
Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid. (1990) (15)
CHAPTER 15 – TUMOR CELL CULTURES IN DRUG DEVELOPMENT (2002) (15)
Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361. (2019) (15)
Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice (2000) (15)
Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers. (2014) (15)
DNA-BINDING NITROHETEROCYCLES AS HYPOXIA-SELECTIVE CYTOTOXINS (1992) (14)
Radical Chemistry and Cytotoxicity of Bioreductive 3-Substituted Quinoxaline Di-N-Oxides. (2016) (14)
Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models (2019) (14)
In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. (2004) (14)
Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid (2004) (14)
Influence of Mustard Group Structure on Pathways of in Vitro Metabolism of Anticancer N-(2-Hydroxyethyl)-3,5-dinitrobenzamide 2-Mustard Prodrugss⃞ (2008) (14)
Proliferative assays for the assessment of radiosensitivity of tumor cell lines using 96-well microcultures (1993) (13)
Hypoxia-selective antitumor agents. 11. Chlorambucil N-oxide: a reappraisal of its synthesis, stability, and selective toxicity for hypoxic cells. (1995) (13)
In Vitro and In Vivo Models for Evaluation of GDEPT (2004) (13)
Cytotoxicity and DNA interaction of the enantiomers of 6-amino-3-(chloromethyl)-1-[(5,6,7-trimethoxyindol-2-yl)carbonyl]indo- line (amino-seco-CI-TMI). (1999) (12)
Differential growth inhibition of cultured mammalian cells: comparison of clinical antitumour agents and amsacrine derivatives. (1984) (12)
Synthesis and cytotoxicity of amino analogues of the potent DNA alkylating agent seco-CBI-TMI (1997) (12)
DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A (2017) (12)
Pathways of Reductive Fragmentation of Heterocyclic Nitroarylmethyl Quaternary Ammonium Prodrugs of Mechlorethamine (2002) (12)
Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors (2019) (11)
Does DNA targeting affect the cytotoxicity and cell uptake of basic nitroquinoline bioreductive drugs? (1994) (11)
Cytokinetic resistance of Lewis lung carcinoma to cyclophosphamide and the amsacrine derivative CI-921. (1986) (11)
Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy. (2010) (10)
The fate of N1'-methanesulphonyl-N4'-(9-acridinyl)-3'-methoxy-2',5'-cyclohexadiene- 1',4'-diimine (m-AQDI), the primary oxidative metabolite of amsacrine, in transformed Chinese hamster fibroblasts. (1990) (10)
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: HYPOXIA‐ACTIVATED PRODRUGS AS ANTITUMOUR AGENTS: STRATEGIES FOR MAXIMIZING TUMOUR CELL KILLING (1995) (9)
Nitroacridines with selective toxicity towards hypoxic mammalian cells: Synthesis and stability of tritiated derivatives (1985) (9)
Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide (2019) (9)
The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins. (2011) (9)
Pulse radiolysis studies on the hypoxia-selective toxicity of a colbalt-mustard complex. (1996) (9)
Nitrogen and sulfur analogues of the secoCI alkylating agent: Synthesis and cytotoxicity (1996) (9)
Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity. (1999) (9)
The design of cobalt(III) complexes of phenazine-1-carboxamides as prointercalators and potential hypoxia-selective cytotoxins. (1999) (9)
Effect of reduction potential on the rate of reduction of nitroacridines by xanthine oxidase and by dihydro-flavin mononucleotide (1991) (9)
Effects of amsacrine and other DNA-intercalating drugs on nuclear and nucleolar structure in cultured V79 Chinese hamster cells and PtK2 rat kangaroo cells. (1985) (8)
Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine. (1987) (8)
Abstract B76: Cellular metabolism, murine pharmacokinetics and preclinical antitumor activity of SN29966, a novel hypoxia‐activated irreversible pan‐HER inhibitor (2009) (8)
Nitroacridines and Nitroquinolines as DNA-Affinic Hypoxia-Selective Cytotoxins (1990) (8)
Nitroimidazole-based "extruded mustards' designed as reductively activated hypoxia-selective cytotoxins. (1996) (8)
Synthesis and Cytotoxicity of Amino‐seco‐DSA: An Amino Analogue of the DNA Alkylating Agent Duocarmycin SA. (1999) (7)
Photodegradation of the benzotriazine 1,4-Di-N-oxide hypoxia-activated prodrug SN30000 in aqueous solution. (2014) (7)
Efficient redox cycling of nitroquinoline bioreductive drugs due to aerobic nitroreduction in Chinese hamster cells. (1995) (6)
Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5. (2000) (6)
Abstract A247: Mechanism of action of the hypoxia-activated irreversible pan-HER inhibitor SN29966. (2011) (6)
Discovery of the hypoxia-activated prodrug SN30000 (2017) (6)
The reaction between nitracrine and glutathione: implications for hypoxic cell radiosensitization and cytotoxicity. (1989) (6)
Decrease in adverse reactions after repeated ivermectin treatment in onchocerciasis (1990) (5)
496 Water-soluble dinitrobenzamide mustard phosphate pre-prodrugs as hypoxic cytotoxins (2004) (5)
Correlation of the radiosensitization potency afforded by nitroacridine intercalators with their electron scavenging efficiency in DNA. (1992) (5)
Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000 (2019) (5)
Nitro analogues of chlorambucil as potential hypoxia-selective anti-tumour drugs. (1990) (5)
Final results of a phase Ib trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, in combination with gemcitabine (G) or docetaxel (D) in patients with advanced solid tumors. (2010) (5)
In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma. (1986) (5)
Crystallographic and oxygen-17 NMR studies of nitro group torsion angles in a series of 4-alkylaminonitroquinolines designed as hypoxia-selective cytotoxins (1992) (5)
Drug‐DNA adducts as biomarkers for metabolic activation of the nitro‐aromatic nitrogen mustard prodrug PR‐104A (2018) (5)
Metabolic and radiolytic reduction of 4-alkylamino-5-nitroquinoline bioreductive drugs. Relationship to hypoxia-selective cytotoxicity. (1994) (5)
Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia. (2013) (4)
Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia. (2009) (4)
A Novel Nitro‐Substituted seco‐CI: Application as a Reductively Activated Adept Prodrug. (1997) (4)
DNA-Directed Alkylating Agents. 6. Synthesis and Antitumor Activity of DNA Minor Groove-Targeted Aniline Mustard Analogs of Pibenzimol. [Erratum to document cited in CA121:300815] (1995) (4)
Nitrogen and Sulfur Analogues of the seco-CI Alkylating Agent: Synthesis and Cytotoxicity. (1997) (4)
Ocular and systemic side effects following ivermectin treatment in onchocerciasis patients from Sierra Leone. (1990) (4)
Studies on the mode of action of the antitumour acridine 4'-(9-acridinylamino)methanesulphon-m-anisidide (m-AMSA) (1978) (4)
Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity (2020) (4)
A phase I pharmacokinetic study of PR-104, a hypoxia-targeting agent, in patients with solid tumors (2007) (3)
Design, Synthesis and Evaluation of Imidazolylmethyl Carbamate Prodrugs of Alkylating Agents. (2000) (3)
Abstract 1660: The antitumor action of ASA404 (vadimezan; DMXAA); potential involvement of vascular endothelial growth factor (VEGF) (2010) (3)
Abstract C46: Design and identification of the novel hypoxia‐activated irreversible pan‐HER inhibitor SN29966 (2009) (3)
DNA-Directed Alkylating Agents. Part 4. 4-Anilinoquinoline-Based Minor Groove Directed Aniline Mustards. (1991) (3)
Weight loss effects of quaternary salts of 5-amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles; structure-activity relationships. (2012) (3)
Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors (2019) (3)
Radiosensitisation of SCCVII tumours and normal tissues in mice by the DNA-dependent protein kinase inhibitor AZD7648. (2021) (3)
The role of immune effector cells in flavone acetic acid-induced injury to tumor cells in EMT6 spheroids. (1992) (3)
473 POSTER The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3 (prostaglandin F synthase) (2008) (3)
Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection (2011) (3)
Sensitive liquid chromatographic assay for the basic DNA intercalator (N,N-dimethylaminoethyl)-9-amino-5-methylacridine-4-carboxamide and its nitroarylmethyl quaternary prodrugs in biological samples. (2001) (2)
An indoline-derived compound that markedly reduces mouse body weight (2013) (2)
N‐Substituted 2‐(2,6‐Dinitrophenylamino)propanamides: Novel Prodrugs That Release a Primary Amine via Nitroreduction and Intramolecular Cyclization. (1999) (2)
Inhibition of tumor blood flow. (2000) (2)
Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug (2021) (2)
Calcium Enabled Remote Loading of a Weak Acid Into pH-sensitive Liposomes and Augmented Cytosolic Delivery to Cancer Cells via the Proton Sponge Effect (2022) (2)
Targeting Tumor Hypoxia with Prodrugs: Challenges and Opportunities (2008) (2)
Abstract 2440: Potentiation of the action of chemotherapeutic drugs by the hypoxia-activated prodrug SN30000 in multicellular tumor spheroids (2018) (2)
Nitrobenzyl Carbamate Prodrugs of Enediynes for Nitroreductase Gene‐Directed Enzyme Prodrug Therapy (GDEPT). (2000) (2)
EF5 as a predictive biomarker for activation of the new hypoxia-targeting prodrug SN30000. (2011) (2)
Molecular determinants of T-cell acute lymphoblastic leukaemia sensitivity to the pre-prodrug PR-104 (2012) (2)
Prodrug Strategies for Targeting Tumour Hypoxia (2014) (2)
Pulse radiolysis studies on the oxidation of OH˙ radical-damaged DNA by nitroquinolines in aqueous solution (1995) (2)
Abstract 41: Role of the novel glucose-phosphorylating enzyme ADP-dependent glucokinase in human cancer cell lines featuring knockouts generated by zinc finger nucleases (2010) (1)
Random clonal expansion as a limiting factor in transplantable in vivo CRISPR/Cas9 screens (2021) (1)
Effect of cell type and drug lipophilicity on the extravascular transport of small molecule anticancer drugs: tirapazamine analogs (2005) (1)
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours (2012) (1)
A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors (2008) (1)
Synthesis and Cytotoxicity of 5-Amino-1-(chloromethyl)-3- [(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-diyhdro-3H-benz[e]indole (Amino-seco-CBI-TMI) and Related 5-Alkylamino Analogues: New DNA Minor Groove Alkylating Agents. (1999) (1)
Development of capability for genome-scale CRISPR-Cas9 knockout screens in New Zealand (2018) (1)
Abstract 2111: Identification of reductases capable of metabolic activation of hypoxia targeting prodrug SN30000 and hypoxia marker EF5. (2013) (1)
Abstract 5306: 18F-EF5 microPET imaging of treatment response from a novel, hypoxia-selective cytotoxin SN30000 in a human lung cancer xenograft model (2011) (1)
258 POSTER Tricyclic triazin 1,4-dioxides: a new class of hypoxia-selective cytotoxins with improved extravascular transport compared to tirapazamine (2006) (1)
Targeting the Leukemia-Associated Hypoxic Microenvironment with Hypoxia-Activated Prodrug PR-104 (2010) (1)
Studies of Naphthalene Diimides as DNA-binding Agents (1997) (1)
Abstract 453: Identification of human oxidoreductases involved in the hypoxia-dependent activation of bioreductive prodrugs (2010) (1)
412P Effects of statins on melanoma (2016) (1)
Abstract 4513: Investigation of bystander effects of hypoxia activated prodrugs using three dimensional cell cultures (2017) (1)
Drugging Tumour Hypoxia: Resolving the Complexity Using Functional Genetic Screens (2015) (0)
Agent-based models for prediction of tumor spheroid response to radiation and the hypoxia-activated prodrug SN30000 (Abstract #4523) (2017) (0)
Compositions of DMXAA and other anticancer agents (2002) (0)
Abstract SY34-01: New prodrugs for targeting tumor hypoxia (2010) (0)
Hypoxia-activated prodrugs of DNA-dependent protein kinase as radiosensitisers (2020) (0)
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit (2021) (0)
Combinations of DMXAA and other anticancer agents. (2002) (0)
259 POSTER Substituted nitro(chloromethyl)benzindolines (nitroCBls): a new class of hypoxia selective cytotoxins with in vivo activity (2006) (0)
Abstract C21: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumor patients. (2011) (0)
Effect of POR knockout on hypoxic prodrug activation (2013) (0)
1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam (2018) (0)
Polymeric Micellar Carriers for a Hydrophobic Anti-cancer Drug (2013) (0)
Final results of a phase I trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, given weekly to solid tumor patients. (2010) (0)
260 POSTER SN 30000: a tricyclic triazine 1,4-dioxide hypoxia-selective bioreductive drug with superior in vivo activity to tirapazamine (2006) (0)
492 Novel hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with improved extravascular transport: analogues of Tirapazamine with in vivo activity (2004) (0)
Crystallographic and 17O NMR Studies of Nitro Group Torsion Angles in a Series of 4-Alkylaminonitroquinolines Designed as Hypoxia-Selective Cytotoxins. (1992) (0)
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit (2021) (0)
Synthesis and Cytotoxicity of Amino Analogues of the Potent DNA Alkylating Agent seco‐CBI‐TMI. (1997) (0)
Remote Loading of a Novel Acidic Hypoxia-Activated Prodrug into Liposomes with High Entrapment Efficiency and Drug Loading Ming ( (2014) (0)
Indane derivatives for antipsychotic agents (1997) (0)
Small Molecule Therapeutics Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer (2014) (0)
Identification of a lead hypoxia-activated irreversible pan-HER inhibitor SN32807 (PR509) by pharmacokinetic and anti-tumor efficacy screening in an erlotinib-resistant xenograft model (2011) (0)
Clinical Cancer esearch cer Therapy : Preclinical rmacokinetic / Pharmacodynamic Modeling Identifies 0000 and SN 29751 as Tirapazamine Analogues with roved Tissue Penetration and Hypoxic R l Killing in Tumors (2010) (0)
PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation (2018) (0)
474 POSTER Relationships between reductive metabolism, DNA crosslinks and antitumor activity of the hypoxia-activated prodrug PR-104 in preclinical models (2008) (0)
S23 03 WA – DNA-BINDING NITROHETEROCYCLES AS HYPOXIA-SELECTIVE CYTOTOXINS (1991) (0)
Nitroanilinderivater and their use as antitumor agents (1992) (0)
204 High-throughput functional screening identifies the flavoreductase POR as a principal determinant of sensitivity to the hypoxia-targeting prodrug SN30000 (2014) (0)
263 POSTER Metabolism and pharmacokinetics of PR-104, a hypoxia-activated nitrogen mustard prodrug in phase I clinical trial (2006) (0)
Abstract PO-018: Hypoxia activated prodrugs of DNA-dependent protein kinase inhibitors as radiosensitisers of head and neck squamous cell carcinomas (2021) (0)
DMD # 30973-1-Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice , Rats , Dogs and Humans (2009) (0)
Hypoxia-Selective Antitumor Agents. Part 14. Synthesis and Hypoxic Cell Cytotoxicity of Regioisomers of the Hypoxia-Selective Cytotoxin 5- (N,N-Bis(2-chloroethyl)amino)-2,4-dinitrobenzamide. (2010) (0)
983 The Role of Bystander Effects in the Anti-tumour Activity of the Hypoxia-activated Prodrug PR-104a (2012) (0)
Hypoxia-Selective Antitumor Agents. Part 7. Metal Complexes of Aliphatic Mustards as a New Class of Hypoxia-Selective Cytotoxins. Synthesis and Evaluation of Cobalt(III) Complexes of Bidentate Mustards. (1993) (0)
The Leukemic Bone Marrow Microenvironment: Targeting Hypoxia with Hypoxia-Activated Prodrugs (2015) (0)
Cobalt and chromium complexes as radiation-activated cytotoxins (1997) (0)
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma (2023) (0)
Abstract 2745: AKR1C3 is a potential biomarker of T-cell acute lymphoblastic leukemia sensitivity to the pre-prodrug PR-104. (2013) (0)
1015 POSTER Evaluation of the Role of the Novel Glucose-phosphorylating Enzyme ADP-dependent Glucokinase in Human Tumour Cell Lines Using Zinc Finger Nuclease Gene Knockouts (2011) (0)
305 POSTER Structure–activity relationships for lipophilic dinitrobenzamide mustards as prodrugs for Escherichia coli NfsB nitroreductase (2008) (0)
Investigation of bystander effects of hypoxia activated prodrugs using three dimensional cell cultures (Abstract #4513) (2017) (0)
247. Sustaining Excellence of Care During a Fluid Shortage: Snapshot of Antibiotic Mitigation Strategies Following Hurricane Maria (2018) (0)
Targeting Hypoxia and AKR1C3 with PR104 in Patients with Acute Leukemia (2012) (0)
LYMPHOID NEOPLASIA AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia (2015) (0)
Quantitative structure-activity relationships for the cytotoxicity of substituted aniline mustards in tissue culture (1989) (0)
Abstract LB-297: Characterization of novel hypoxia-activated prodrugs of irreversible pan-HER inhibitors (2010) (0)
the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non-Small Cell Lung Cancer Xenograft Model (2013) (0)
Hypoxia‐Selective Antitumor Agents. Part 8. Bis(nitroimidazolyl) alkanecarboxamides: A New Class of Hypoxia‐Selective Cytotoxins and Hypoxic Cell Radiosensitisers. (1994) (0)
Abstract 4523: Agent-based models for prediction of tumor spheroid response to radiation and the hypoxia-activated prodrug SN30000 (2017) (0)
Functional genomics screens to identify genes involved in tolerance of tumour microenvironment stress (2020) (0)
Erratum to: Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice (2011) (0)
Plateau-Phase Chinese Hamster Fibroblast Cell Cultures Uptake , Metabolism , and DNA Breakage in Log-and-anisidide : Comparison of m-( 9-Acridinylamino ) methanesulfon-′ Mechanism of Resistance of Noncycling Mammalian Cells to 4 Updated (2006) (0)
498 Selective potentiation of the hypoxic cytotoxicity of the bioreductive drug tirapazamine (2004) (0)
1,2,4-tri-cyclic triazinoxide and compositions thereof for the therapeutic application in cancer treatment (2006) (0)
Abstract 5853: Identification ofTSC1andTSC2as potential determinants of sensitivity to trastuzumab emtansine (2020) (0)
203 Hypoxic Leukemic Microenvironment and its Targeting by the Hypoxia-Activated Prodrug PR-104 (2011) (0)
Pharmacodynamic biomarkers for the hypoxia-activated nitrogen mustard PR-104; DNA interstrand crosslinks and γH2AX in human tumor cell lines and xenografts (2007) (0)
300 POSTER Oncolytic adenovirus ONYX-411NTR enhances the antitumour efficacy of the bioreductive alkylator prodrug PR-104 (2008) (0)
Abstract 2272: Comparison of bioreductive metabolism of tirapazamine, its second generation analogue SN 30000 and hypoxia imaging agent EF5 in human tumor cell lines (2010) (0)
Abstract 169: Preclinical efficacy and sensitivity determinants of evofosfamide in molecularly defined models of head and neck squamous cell carcinoma (2017) (0)
P32 21 TP – PULSE RADIOLYSIS STUDIES OF INTRAMOLECULAR ELECTRON TRANSFER IN DNA TO ELECTRON-AFFINIC INTERCALATORS (1991) (0)
Expression and role in glycolysis of human ADP-dependent glucokinase (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William Robert Wilson?

William Robert Wilson is affiliated with the following schools:

William Robert Wilson's Academic­Influence.com Rankings

William Robert Wilson's Degrees

Why Is William Robert Wilson Influential?

William Robert Wilson's Published Works

Published Works

What Schools Are Affiliated With William Robert Wilson?

William Robert Wilson's AcademicInfluence.com Rankings